Biotech Co.*
(Country; Symbol)

Pharma Co. (Country)


Terms/Details (Date)

Alpha Innotech

Panomics Inc.

FluorChem fluorescence and chemiluminescence imaging system and the TranSignal chemiluminescense- based membrane array products

Strategic alliance to jointly market their respective products (2/25)

Atrix Laboratories
Inc. (ATRX)

Luxembourg Pharmaceuticals
Ltd. (Israel)

Eligard leuprolide acetate prostate cancer products

Exclusive licensing agreement for the Israeli marketing rights to Atrix's four Eligard leuprolide acetate prostate cancer products; Atrix will get a royalty on net sales; Luxembourg will be responsible for regulatory submissions and any studies necessary to gain approval in Israel; Atrix will manufacture the products (3/8)


Cambrex Corp.

MyoCell therapy

Supply agreement in which Cambrex will contract manufacture BioHeart's autologous MyoCell therapy; Cambrex will support BioHeart's worldwide trials (3/12)

Genzyme Transgenics Corp. (GZTC)

Fresenius AG (Germany)

Recombinant human serum albumin (rhSA)

Fresenius gained rights to market rhSA in Japan; it paid $1.2M for the rights; it already had rights in Europe, North America and the rest of Asia (4/8)

IDEC Pharma-
Corp. (IDPH)

Syncor International Corp.

Zevalin (ibritumomab tiuxetan

Syncor will prepare and distribute patient-specific doses of Zevalin (2/28)

Ligand Pharma-

Royalty Pharma AG (Switzerland)

Three late-stage selective estrogen receptor modulator products

Ligand was paid $6M in exchange for a right to receive 0.25% of net sales of the products for a period of 10 years; Royalty has options to purchase at escalating prices additional rights to receive up to 1% of the products' net sales for a period of 10 years, for a total of $56M (3/7)

NextGen Sciences Ltd. (UK)*


ProteinArray Workstation

PerkinElmer Life Sciences will manufacture and have exclusive worldwide distribution rights to the system (3/12)

Sanguine Corp.*

Ascendiant-South America LLC (affiliate of Ascendiant Capital Group Inc.)


Agreement is for Ascendiant to begin manufacturing and distribution of PHER-02 in major countries in South America; PHER-02 is an oxygen-carrying synthetic substitute for human red blood cells (4/3)

Senetek plc

Enprani Co. Ltd. (Korea)


Agreement for Enprani to market and distribute Kinetin in South Korea; the licensing agreement calls for an undisclosed up-front royalty payment to Senetek, guaranteed annual minimum sales and royalties on future products sold; the companies will collaborate on the manufacture of the Kinetin products (4/16)

Viragen Inc.

AGC (Pakistan) and Metdem Healthcare Ltd. (Turkey)

Natural alpha interferon, Multiferon

Viragen has two agreements with international drug distributors for its natural alpha interferon, Multiferon; AGC will distribute it in the Middle East and Metdem Healthcare will distribute it in Turkey; deal is worth $22M (4/3)


# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; NYSE = New York Stock Exchange